Novo Nordisk A/S (NEO:NVON)
Canada · Delayed Price · Currency is CAD | Market Cap | 240.40B -29.0% |
| Revenue (ttm) | 71.49B +5.6% |
| Net Income | 25.27B +4.8% |
| EPS | 5.68 +5.0% |
| Shares Out | n/a |
| PE Ratio | 9.51 |
| Forward PE | 11.93 |
| Dividend | 0.04 (1.00%) |
| Ex-Dividend Date | Aug 17, 2026 |
| Volume | 2,070 |
| Open | 4.100 |
| Previous Close | 4.140 |
| Day's Range | 4.100 - 4.100 |
| 52-Week Range | 3.700 - 6.630 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo vs. Eli Lilly: Study Shows Ozempic Advantage over Mounjaro — Why This Matters for NVO Investors
Danish drug giant Novo ($NVO), in a Tuesday press statement, announced key findings from a real-world study that pitched its diabetes drug against Eli Lilly’s ($LLY). The study compared semaglutide,…
Novo Nordisk enters into license agreement with Hengrui Pharma on HRS-1596
The company stated: “Novo Nordisk (NVO) announced that it has entered into a license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor, (GLP-1R, and gastric ...
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
Novo Nordisk said on Tuesday a real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compa...
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
Eli Lilly said its oral obesity drug, Foundayo, offers greater weight loss and better blood sugar control than a higher dose of Novo Nordisk's Ozempic pill in adults with type 2 diabetes, citing dat...
Novo Nordisk announces retrospective RWE on Ozempic in type 2 diabets
Novo Nordisk (NVO) announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg. In the analysis, adults who escalated to semaglut...
Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
The Danish drugmaker signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion.
China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
Jiangsu Hengrui Pharmaceuticals , China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S in a deal w...
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb's Growth Portfolio sales rose 15% in the second quarter, and management raised its 2026 revenue guidance to $49 billion to $50 billion. Novo Nordisk expects 2026 adjusted sales to...
Could This Be Novo Nordisk's Next Billion-Dollar Weight-Loss Product?
Novo Nordisk needs new products to better compete with Eli Lilly in the weight loss market. Zenagamtide is one of its promising candidates and could, eventually, generate over $1 billion in annual sal...
Novo Nordisk, Nanexa enter global license agreement for injectables
Nanexa AB, a Swedish drug delivery platform company developing long-acting injectable drugs based on its proprietary PharmaShell technology platform, announces that it has entered into a global exclus...
NTHM's Index Rebalance Puts Thematic Rotation to Work
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP...
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share. Meanwh...
Pharma stock soars 150% on injectables deal with Wegovy maker Novo
The Swedish drug-delivery company agreed to license its PharmaShell technology to Novo Nordisk for up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditio...
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring
Just days after a capital-markets day left investors wondering what's next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
Novo Nordisk agreed to license and develop the technology, which could cut the frequency patients need to inject its obesity and diabetes drugs.
Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Shares in Swedish drug-delivery company Nanexa more than doubled their value in early Friday trading after it signed a global licensing deal with Novo Nordisk worth up to about €1.17 billion ($1.33 ...
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
AbbVie maintains a diversified revenue base by expanding its presence in immunology, neuroscience, and oncology to offset patent cliffs. Novo Nordisk leverages its leadership in the diabetes and obesi...
Novo's new strategy hinges on something it can't manufacture: investor trust
Novo set out ambitions to launch more than five potential multi-blockbuster drugs by 2030 on Monday, but shares fell 8%. Analysts said the update offered little new to restore confidence after the com...
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their we...
Novo Nordisk says CagriSema delivers ‘superior’ weight loss in REIMAGINE 5 trial
Novo Nordisk (NVO) this week announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema, an investigational product, and Novo’s next innovation in weight…
Not Palantir. Not Micron.
Jensen Huang says cybersecurity is the next major use case for artificial intelligence. Cybersecurity is one of the more compute-intensive uses of AI because the inference workloads must run continuou...
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
To see whether Novo Nordisk NYSE: NVO is closing the gap with competitor Eli Lilly NYSE: LLY in the GLP-1 market, investors need only look at patent-cliff timing and current market share. Eli Lilly co...
Novo is open to upgrading its New York listing to boost US profile, FT says
Novo (NVO) is open to upgrading its New York listing to boost its profile in the U.S., following a similar move by AstraZeneca (AZN) earlier in the year, Aanu Adeoye,…
Novo wants to change how Wall Street owns its stock: why now
Novo Nordisk wants a bigger presence on Wall Street, and the timing may say more about the drugmaker's challenges than the listing itself. Chief executive Mike Doustdar said Novo could see advantages ...